Arrowhead Pharmaceuticals announced that it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and growth opportunities across Arrowhead’s robust and diverse pipeline of RNAi therapeutics. The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead’s option, subject to mutual agreement between Sixth Street and Arrowhead, during the seven-year term of the agreement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- ARWR Upcoming Earnings Report: What to Expect?
- B. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nod
- Arrowhead price target lowered to $60 from $90 at H.C. Wainwright
- Arrowhead to advance plozasiran into Phase 3 cardiovascular outcomes trial
- Arrowhead presents preclinical data on new ARO-INHBE